相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E. Kohrt et al.
BLOOD (2014)
B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies
K. Bojarczuk et al.
LEUKEMIA (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2013)
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib
Nicole Hassold et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity
Magdalena Winiarska et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Novel therapeutic agents for B-cell lymphoma: developing rational combinations
Craig B. Reeder et al.
BLOOD (2011)
Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells
Paul V. Beum et al.
JOURNAL OF IMMUNOLOGY (2011)
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
Michael G. Kharas et al.
BLOOD (2010)
Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity
Jacek Bil et al.
BLOOD (2010)
Antifungal Therapy with Itraconazole Impairs the Anti-Lymphoma Effects of Rituximab by Inhibiting Recruitment of CD20 to Cell Surface Lipid Rafts
Ingo Ringshausen et al.
CANCER RESEARCH (2010)
In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
Simone de Haij et al.
CANCER RESEARCH (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Junji Hiraga et al.
BLOOD (2009)
Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy
Akiko Miyagi Maeshima et al.
CANCER SCIENCE (2009)
Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
Yasuhito Terui et al.
CLINICAL CANCER RESEARCH (2009)
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
Cara K. Fraser et al.
EXPERIMENTAL HEMATOLOGY (2009)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth
Jiyuan Ke et al.
MOLECULAR CANCER (2009)
Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients
Aylin Sar et al.
LEUKEMIA RESEARCH (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Dasatinib suppresses in vitro natural killer cell cytotoxicity
Stephen J. Blake et al.
BLOOD (2008)
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils
Michael Kneidinger et al.
BLOOD (2008)
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib
C. Yang et al.
LEUKEMIA (2008)
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20
Magdalena Winiarska et al.
PLOS MEDICINE (2008)
Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts
Sebastien Tauzin et al.
BLOOD (2008)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Linfeng Chen et al.
BLOOD (2008)
Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors
Eric C. Peters et al.
ACS CHEMICAL BIOLOGY (2007)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Epigenetic regulation of CD20 protein expression in a novel B-Cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy
Akihiro Tomita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity
Tom van Meerten et al.
CLINICAL CANCER RESEARCH (2006)
Epigenetic processes play a major role in B-cell-specitic gene silencing in classical Hodgkin lymphoma
A Ushmorov et al.
BLOOD (2006)
Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab
RM Seliem et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2006)
The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
PV Beum et al.
JOURNAL OF IMMUNOLOGY (2006)
Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway
J Jaworski et al.
JOURNAL OF NEUROSCIENCE (2005)
Src kinases as targets for B cell acute lymphoblastic leukaemia therapy
SG Li
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
I Jilani et al.
BLOOD (2003)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Loss of CD20 expression in relapsed lymphomas after rituximab therapy
JH Haidar et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab
T Pickartz et al.
EXPERIMENTAL HEMATOLOGY (2001)
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis
JM Foran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
